'We kept at it': Jeffrey Bluestone plots late-stage comeback after teplizumab shown to delay type 1 diabetes
Late-stage data presented at the American Diabetes Association annual meeting in 2010 pushed Eli Lilly to put a crimp on teplizumab as the pharma giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.